全球儿童HIV感染者抗逆转录病毒治疗可及性:IeDEA队列2004-2015年前瞻性研究
该研究基于IeDEA全球队列联盟135,479名0-19岁HIV感染儿童,分析2004至2015年从入组到启动抗逆转录病毒治疗(ART)的时间。24个月ART启动累积发生率为68.2%,撒哈拉以南非洲地区较低,且 adolescents 和婴儿启动率最低,启动前失访风险高。
要点
- 24个月ART启动累积发生率为68.2%,地区差异显著。
- 15-19岁青少年和<1岁婴儿ART启动率最低。
- 启动前失访率达20.4%,可能掩盖未记录死亡。
核心结论
- 68%的HIV感染儿童在24个月内启动ART,但启动前失访风险高,存在显著不公平。
主要发现
- 99,404名(73.4%)儿童启动ART,1.9%死亡,1.4%转出,20.4%在启动前失访。
- 24个月ART启动累积发生率为68.2%(95% CI: 67.9%-68.4%)。
- 撒哈拉以南非洲24个月累积发生率从49.8%(中非,95% CI: 48.4%-51.2%)到72.5%(西非,95% CI: 71.5%-73.5%)。
- 15-19岁青少年和<1岁婴儿24个月累积发生率分别为62.2%(95% CI: 61.6%-62.8%)和66.4%(95% CI: 65.7%-67.0%)。
- 基线时49.1%符合当地指南ART条件,其中80.6%启动ART。
关键数值与推荐
- 女性、<1岁、2-4岁、5-9岁、15-19岁、随访期间变为符合条件者、低收入或中低收入国家就医者ART启动累积发生率较低(p < 0.01)。
临床怎么用
- 需针对青少年和婴儿等重点人群加强ART启动干预,并减少启动前失访。
局限性
- 存在左截断和幸存者偏倚,因入组前死亡导致。
- 使用入组日期替代缺失的HIV诊断日期,可能低估诊断到ART启动的时间。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Access to antiretroviral therapy (ART) is a global priority. However, the attrition across the continuum of care for HIV-infected children between their HIV diagnosis and ART initiation is not well known. We analyzed the time from enrollment into HIV care to ART initiation in HIV-infected children within the International Epidemiology Databases to Evaluate AIDS (IeDEA) Global Cohort Consortium. METHODS AND FINDINGS: We included 135,479 HIV-1-infected children, aged 0-19 years and ART-naïve at enrollment, between 1 January 2004 and 31 December 2015, in IeDEA cohorts from Central Africa (3 countries; n = 4,948), East Africa (3 countries; n = 22,827), West Africa (7 countries; n = 7,372), Southern Africa (6 countries; n = 93,799), Asia-Pacific (6 countries; n = 4,045), and Latin America (7 countries; n = 2,488). Follow-up in these cohorts is typically every 3-6 months. We described time to ART initiation and missed opportunities (death or loss to follow-up [LTFU]: last clinical visit >6 months) since baseline (the date of HIV diagnosis or, if unavailable, date of enrollment). Cumulative incidence functions (CIFs) for and determinants of ART initiation were computed, with death and LTFU as competing risks. Among the 135,479 children included, 99,404 (73.4%) initiated ART, 1.9% died, 1.4% were transferred out, and 20.4% were lost to follow-up before ART initiation. The 24-month CIF for ART initiation was 68.2% (95% CI: 67.9%-68.4%); it was lower in sub-Saharan Africa-ranging from 49.8% (95% CI: 48.4%-51.2%) in Central Africa to 72.5% (95% CI: 71.5%-73.5%) in West Africa-compared to Latin America (71.0%, 95% CI: 69.1%-72.7%) and the Asia-Pacific (78.3%, 95% CI: 76.9%-79.6%). Adolescents aged 15-19 years and infants <1 year had the lowest cumulative incidence of ART initiation compared to other ages: 62.2% (95% CI: 61.6%-62.8%) and 66.4% (95% CI: 65.7%-67.0%), respectively. Overall, 49.1% were ART-eligible per local guidelines at baseline, of whom 80.6% initiated ART. The following children had lower cumulative incidence of ART initiation: female children (p < 0.01); those aged <1 year, 2-4 years, 5-9 years, and 15-19 years (versus those aged 10-14 years, p < 0.01); those who became eligible during follow-up (versus eligible at enrollment, p < 0.01); and those receiving care in low-income or lower-middle-income countries (p < 0.01). The main limitations of our study include left truncation and survivor bias, caused by deaths of children prior to enrollment, and use of enrollment date as a proxy for missing data on date of HIV diagnosis, which could have led to underestimation of the time between HIV diagnosis and ART initiation. CONCLUSIONS: In this study, 68% of HIV-infected children initiated ART by 24 months. However, there was a substantial risk of LTFU before ART initiation, which may also represent undocumented mortality. In 2015, many obstacles to ART initiation remained, with substantial inequities. More effective and targeted interventions to improve access are needed to reach the target of treating 90% of HIV-infected children with ART.
引用
- Desmonde S, Tanser F, Vreeman R, et al. Access to antiretroviral therapy in HIV-infected children aged 0-19 years in the International Epidemiology Databases to Evaluate AIDS (IeDEA) Global Cohort Consortium, 2004-2015: A prospective cohort study. PLoS Med. 2018. PMID: 29727458. doi:10.1371/journal.pmed.1002565
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。